$16.07
0.92% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

ACADIA Pharmaceuticals Inc. Stock price

$16.07
-2.78 14.75% 1M
-7.13 30.73% 6M
-15.24 48.67% YTD
-11.04 40.72% 1Y
-0.71 4.23% 3Y
-7.73 32.48% 5Y
-11.86 42.46% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.15 0.92%
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

Key metrics

Market capitalization $2.67b
Enterprise Value $2.22b
P/E (TTM) P/E ratio 90.03
EV/FCF (TTM) EV/FCF 27.61
EV/Sales (TTM) EV/Sales 2.50
P/S ratio (TTM) P/S ratio 2.99
P/B ratio (TTM) P/B ratio 5.16
Revenue growth (TTM) Revenue growth 61.65%
Revenue (TTM) Revenue $890.53m
EBIT (operating result TTM) EBIT $22.82m
Free Cash Flow (TTM) Free Cash Flow $80.48m
Cash position $500.94m
EPS (TTM) EPS $0.18
P/E forward 28.95
P/S forward 2.80
EV/Sales forward 2.33
Short interest 8.69%
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

13x Buy
68%
5x Hold
26%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
68%
Hold
26%
Sell
5%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
891 891
62% 62%
100%
- Direct Costs 74 74
439% 439%
8%
817 817
52% 52%
92%
- Selling and Administrative Expenses 423 423
12% 12%
47%
- Research and Development Expense 360 360
26% 26%
40%
34 34
128% 128%
4%
- Depreciation and Amortization 12 12
261% 261%
1%
EBIT (Operating Income) EBIT 23 23
118% 118%
3%
Net Profit 31 31
128% 128%
3%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
10 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. Eastern...
Negative
Seeking Alpha
12 days ago
Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward.
Neutral
Business Wire
25 days ago
SAN DIEGO--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson's disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson's®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson's disease – ...
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Stephen Davis
Employees 598
Founded 1993
Website www.acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today